Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dabigatran etexilate - Boehringer Ingelheim

Next Previous
Drug Profile

Dabigatran etexilate - Boehringer Ingelheim

Alternative Names: BIBR 953; BIBR 953 ZW; BIBR-1048; BIBR-1048MS; Dabigatran; Dabigatran etexilate mesilate; Dabigatran etexilate mesylate; Dabigatran etexilate methanesulfonate; Pradax; Pradaxa; Pradaxar; Prazaxa

Latest Information Update: 24 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Population Health Research Institute
  • Class Amines; Antiarrhythmics; Anticoagulants; Antihaemorrhagics; Antithrombotics; Benzimidazoles; Carboxylic acids; Cardiovascular therapies; Esters; Pyridines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
  • Phase III Cardiomyopathies; Cardiovascular disorders; Gastrointestinal haemorrhage; Vascular disorders
  • Discontinued Acute coronary syndromes

Most Recent Events

  • 19 Nov 2025 Launched for Venous thromboembolism (In adolescents, In children) in European Union (PO)
  • 19 Nov 2025 Launched for Venous thromboembolism (In adolescents, In children) in Iceland (PO)
  • 19 Nov 2025 Launched for Venous thromboembolism (In adolescents, In children) in Norway (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top